On November 4, 2026 TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, reported that it would present three posters on its research on the role of the Delta Opioid Receptor (DOR) in controlling the immunosuppressive capabilities of Myeloid-Derived Suppressor Cells (MDSCs) at the upcoming 68th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition taking place on December 12-15, 2026, in New Orleans, Louisiana.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We continue to be impressed by uncovering the central role the DOR plays in proliferation, recruitment and immune suppressing capabilities across MDSCs, T regs and M2 macrophages, the 3 most important naturally occurring immune suppressing cells in the body. These immune suppressing cells are an important mechanism for the body to calm chronic inflammation, but when highjacked in the setting of cancer, they are known to be culprits in resistance to and failure of cancer immunotherapy," said Dr. James Bianco, President and Chief Executive Officer of TuHURA Biosciences. "In addition to providing information critical to multiple patent submissions, the data underscore the breadth of the potential therapeutic applications for DOR technology in the development of a first new class of non-tumor targeting, immune modulating ADCs."
Poster Presentation Details:
Abstract Number: 4725
Title: Inhibition of the delta opioid receptor (DOR) on myeloid-derived suppressor cells (MDSCs) significantly reduces Cxcl10, Saa3 and Acod1 gene expression, representing a single target to modulate MDSC proliferation, migration and immune suppression.
Presenter: Dr. Krit Ritthipichai, Director of Immunology
Session: 201. Granulocytes, Monocytes, and Macrophages: Poster III
Date and Time: Monday, December 14, 2026, 6:00pm to 8:00pm ET
Location: MCCNO – Hall F
Abstract Number: 4721
Title: Delta opioid receptor (DOR) inhibition drives both proenkephalin (PENK) gene expression and met-enkephalin (mENK) protein in tumor-derived myeloid-derived suppressor cells (tMDSC) and bone marrow-derived macrophage subtype 2 (BMDM2): Implications for modulation of immune suppression in cancer and autoimmune disease.
Presenter: Dr. Taekyoung Kwak, Lead Scientist, Immunology and Dr. Krit Ritthipichai, Director of Immunology
Session: 201. Granulocytes, Monocytes, and Macrophages: Poster III
Date and Time: Monday, December 14, 2026, 6:00pm to 8:00pm ET
Location: MCCNO – Hall F
Abstract Number: 4744
Title: Delta opioid receptor (DOR) inhibition drives both proenkephalin (PENK) gene expression and met-enkephalin (mENK) protein in tumor-derived myeloid-derived suppressor cells (tMDSC) and bone marrow-derived macrophage subtype 2 (BMDM2): Implications for modulation of immune suppression in cancer and autoimmune disease.
Presenter: Dr. Krit Ritthipichai, Director of Immunology
Session: 201. Granulocytes, Monocytes, and Macrophages: Poster III
Date and Time: Monday, December 14, 2026, 6:00pm to 8:00pm ET
Location: MCCNO – Hall F
(Press release, TuHURA Biosciences, NOV 4, 2026, View Source [SID1234674212])